| HIV Infections

Cabenuva vs Pifeltro

Side-by-side clinical, coverage, and cost comparison for hiv infections.

Deep comparison between: Cabenuva vs Pifeltro with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsPifeltro has a higher rate of injection site reactions vs Cabenuva based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Pifeltro but not Cabenuva, including UnitedHealthcare

Category

Cabenuva

Pifeltro

At A Glance

RouteIM injection (gluteal)

FrequencyEvery 4 weeks or every 8 weeks

ClassINSTI + NNRTI combination

RouteOral

FrequencyOnce daily

ClassNNRTI

Indications

HIV Infections

HIV Infections

Dosing

HIV Infections (Monthly Dosing) Initiation: cabotegravir 600 mg IM + rilpivirine 900 mg IM on last day of current antiretroviral therapy or oral lead-in; Continuation: cabotegravir 400 mg IM + rilpivirine 600 mg IM every month thereafter. Separate gluteal injection sites required.

HIV Infections (Every 2-Month Dosing) Initiation: cabotegravir 600 mg IM + rilpivirine 900 mg IM on last day of current antiretroviral therapy or oral lead-in, repeated 1 month later; Continuation: cabotegravir 600 mg IM + rilpivirine 900 mg IM every 2 months thereafter. Separate gluteal injection sites required.

HIV Infections One 100 mg tablet orally once daily with or without food in adults and pediatric patients weighing at least 35 kg.

HIV Infections (with rifabutin) One 100 mg tablet orally twice daily (approximately 12 hours apart) for the duration of rifabutin co-administration.

Contraindications

Previous hypersensitivity reaction to cabotegravir or rilpivirine
Carbamazepine, oxcarbazepine, phenobarbital, phenytoin (anticonvulsants)
Rifabutin, rifampin, rifapentine (antimycobacterials)
Dexamethasone (systemic, more than single dose)
St. John's wort (Hypericum perforatum)

Co-administration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin (anticonvulsants)
Co-administration with enzalutamide (androgen receptor inhibitor)
Co-administration with rifampin or rifapentine (antimycobacterials)
Co-administration with mitotane (cytotoxic agent)
Co-administration with St. John's wort (Hypericum perforatum)

Drug Interactions

778View drug interactions

935View drug interactions

Adverse Reactions

Most common (>=2%) Injection site reactions (pain/discomfort, nodules, induration, swelling, erythema, pruritus, bruising/discoloration, warmth, hematoma), pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, rash

Serious Hypersensitivity reactions including angioedema and urticaria, hepatotoxicity, depression and suicidal ideation/attempt, severe skin reactions including DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis

Postmarketing Hypersensitivity reactions, nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS, Stevens-Johnson syndrome, toxic epidermal necrolysis

Most common (>=5%) Nausea, headache, fatigue, diarrhea, abdominal pain

Postmarketing Stevens-Johnson syndrome/toxic epidermal necrolysis, hepatitis, hepatic enzyme increased

Pharmacology

Cabotegravir inhibits HIV integrase by binding to the active site and blocking the strand transfer step essential for HIV replication. Rilpivirine is an NNRTI that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.

Doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 that inhibits viral replication by non-competitive inhibition of HIV-1 reverse transcriptase and does not inhibit human cellular DNA polymerases alpha, beta, or mitochondrial DNA polymerase gamma.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Cabenuva